Mankind Pharma's Q1 FY 2025-26 Quarterly Results

Result Summary

• Mankind Pharma Ltd reported a 44.1% quarter-on-quarter (QoQ) increase in its consolidated revenues for the quarter-ended Jun (Q1 FY 2025-26). On a year-on-year (YoY) basis, it witnessed a growth of 21.9%.
• Its expenses for the quarter were up by 58.5% QoQ and 33.6% YoY.
• The net profit decreased 6.7% QoQ and decreased 18.1% YoY.
• The earnings per share (EPS) of Mankind Pharma Ltd stood at 10.6 during Q1 FY 2025-26.

Financial Statments for Q1 FY 2025-26

Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results

Company Overview

Mankind Pharma Ltd is a prominent player in the pharmaceutical industry, primarily engaged in developing, manufacturing, and marketing a variety of pharmaceutical formulations. The company has established a strong presence in the Indian market with a diverse range of products that include prescription medicines, over-the-counter (OTC) products, and consumer healthcare products. While specific recent developments for the company are not available, Mankind Pharma is known for its focus on affordable healthcare solutions and a significant market share in the Indian pharmaceutical sector. The company's operations are not limited to India, as it also has a growing international footprint, though further details on recent expansions or strategic initiatives are not provided.

Revenue

In Q1FY26, Mankind Pharma Ltd reported total income of ₹3650.23 crores, representing a substantial increase compared to the previous quarter (Q4FY25), which had total income of ₹2533.23 crores. This reflects a quarter-over-quarter (QoQ) growth of 44.1%. When compared to the same quarter of the previous year (Q1FY25), where total income was ₹2994.02 crores, the company achieved a year-over-year (YoY) growth of 21.9%. These figures highlight a period of significant revenue growth for the company on both quarterly and annual bases.

Profitability

The financial data for Mankind Pharma Ltd's profitability indicates that the company had a profit before tax of ₹537.32 crores in Q1FY26. This amount shows a decrease from ₹569.16 crores in Q4FY25, marking a QoQ decline of 5.6%. On a YoY basis, the decline is more pronounced, with a 19.0% reduction from ₹663.71 crores in Q1FY25. The tax expense for Q1FY26 was ₹95.87 crores, marginally higher by 0.9% compared to the previous quarter, while it decreased by 23.0% compared to Q1FY25. Consequently, the profit after tax was ₹444.62 crores in Q1FY26, showing a QoQ decrease of 6.7% from ₹476.59 crores in Q4FY25, and an 18.1% decline from ₹543.07 crores in Q1FY25. The earnings per share (EPS) for Q1FY26 was ₹10.60, down from ₹11.70 in the previous quarter and ₹13.40 in the same quarter last year, reflecting declines of 9.4% QoQ and 20.9% YoY.

Operating Metrics

For Mankind Pharma Ltd, the total expenses for Q1FY26 amounted to ₹3112.91 crores, which is a significant increase of 58.5% compared to ₹1964.07 crores in Q4FY25. On a YoY comparison, total expenses increased by 33.6% from ₹2330.31 crores reported in Q1FY25. These figures suggest that the company experienced a notable rise in its operational expenditures over the periods in question. While the specific breakdown of these expenses is not detailed, the data indicates a larger scale of operational activities or cost increments during this quarter. The increase in total expenses was greater than the increase in total income over the same periods, which may have implications on the company's operational strategies or market conditions affecting cost structures.